Generation Bio Co. (NASDAQ:GBIO) The stock’s Relative Strength Index (RSI) is 60.82, with weekly volatility at 5.72% and ATR at 2.06. The GBIO stock’s 52-week price range has touched low of $17.00 and a $55.72 high. Its shares traded higher over the last trading session, gaining 6.60% on 05/27/21. The shares fell to a low of $32.4925 before closing at $34.72. Intraday shares traded counted 0.65 million, which was -40.04% lower than its 30-day average trading volume of 461.19K. GBIO’s previous close was $32.57 while the outstanding shares total 55.37M.
Investors have identified the Biotechnology company Generation Bio Co. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $2.03 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Generation Bio Co. (GBIO) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 455.79 million total, with 10.79 million as their total liabilities.
GBIO were able to record -23.94 million as free cash flow during the 08/10/2021 quarter of the year, this saw their quarterly net cash flow reduce by 303.42 million. In cash movements, the company had a total of -23.03 million as operating cash flow.
Having a look at the company’s valuation, the company is expected to record -1.87 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on GBIO sounds very interesting.
Is the stock of GBIO attractive?
In related news, CHIEF SCIENTIFIC OFFICER, Stanton Matthew sold 400 shares of the company’s stock in a transaction that recorded on May 11. The sale was performed at an average price of 31.05, for a total value of 12,420. As the sale deal closes, the CHIEF SCIENTIFIC OFFICER, Stanton Matthew now sold 8,600 shares of the company’s stock, valued at 263,114. Also, PRESIDENT AND CEO, MCDONOUGH GEOFF sold 10,000 shares of the company’s stock in a deal that was recorded on Apr 23. The shares were price at an average price of 35.10 per share, with a total market value of 351,000. Following this completion of acquisition, the CHIEF SCIENTIFIC OFFICER, Stanton Matthew now holds 1,500 shares of the company’s stock, valued at 51,045. In the last 6 months, insiders have changed their ownership in shares of company stock by 20.10%.
6 out of 6 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on Generation Bio Co.. 0 analysts has assigned a Sell rating on the GBIO stock. The 12-month mean consensus price target for the company’s shares has been set at $43.33.